ZIM
RIGL icon

Zacks Investment Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Zacks Investment Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-119,088
Closed -$5.1M – 801
2025
Q4 		$5.1M Sell
119,088
-9,143
-7% -$345K 0.04% 224
2025
Q3 		$3.63M Sell
128,231
-7,614
-6% -$228K 0.03% 261
2025
Q2 		$2.54M Buy
135,845
+7,757
+6% +$147K 0.02% 294
2025
Q1 		$2.3M Buy
128,088
+42,665
+50% +$866K 0.02% 304
2024
Q4 		$1.44M Buy
+85,423
New +$1.64M 0.01% 374
2024
Q3 		– Sell
-39,016
Closed -$321K – 756
2024
Q2 		$321K Sell
39,016
-3,412
-8% -$35.7K ﹤0.01% 499
2024
Q1 		$628K Buy
42,428
+12,193
+40% +$164K 0.01% 448
2023
Q4 		$438K Buy
+30,235
New +$309K 0.01% 482

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zacks Investment Management's RIGL Position: Q1 2026 in Review

Zacks Investment Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2026, closing a stake of 119,088 shares — an estimated $5.1M sold.

Zacks Investment Management first reported a position in RIGL in Q4 2023 and held it in 8 quarters. The position peaked at $5.1M in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Zacks Investment Management reported no remaining Rigel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Zacks Investment Management sold 119,088 Rigel Pharmaceuticals shares in Q1 2026, an estimated $5.1M.
  • Zacks Investment Management first reported a position in Rigel Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Zacks Investment Management's Rigel Pharmaceuticals position peaked at $5.1M in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Zacks Investment Management's 13F filing for Q1 2026, filed 14 May 2026.